Pharmacokinetics of mitomycin C (MMC) after intraperitoneal administration of MMC-gelatin gel and its anti-tumor effects against sarcoma-180 bearing mice

Journal of Drug Targeting

Volumn 4, Issue 5, 1997, Pages 289-296

  Fujita, Takuya ^a   Tamura, Takashi ^a   Yamada, Hidenori ^a   Yamamoto, Akira ^a   Muranishi, Shozo ^a  

^a KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Gelatin; Mitomycin C; Pharmacokinetics; Sarcoma 180; Tumor bearing mice

Indexed keywords

ANTINEOPLASTIC AGENT; GELATIN; MITOMYCIN C;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CANCER SURVIVAL; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DIFFUSION; DRUG FORMULATION; DRUG RELEASE; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MEAN RESIDENCE TIME; MOUSE; NONHUMAN; PERITONEAL CAVITY; PHARMACOKINETICS; PRIORITY JOURNAL; RAT; SARCOMA 180; SURVIVAL TIME; VISCOSITY;

EID: 0030927044     PISSN: 1061186X     EISSN: None     Source Type: Journal    
DOI: 10.3109/10611869708995844     Document Type: Article

References (23)

1. Cheong, L. W. S., Heng, P. W. S. and Wong, L. F. (1992) Relationship between polymer viscosity and drug release from a matrix system. Pharm Res. 9, 1510-1514
2. Dedrick, R. L., Meyers, C. E., Bungay, P. M. and Devita, V. T. V., Jr. (1978) Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat. Rep. 62, 1-9.
3. Fidler, I. J. and Hart, I. R. (1982) Biological diversity in metastatic neoplasms: origin and implications. Science 217, 998-1003.
4. Fidler, I. J. (1985) Macrophages and metastasis - a biological approach to cancer therapy: presidential address. Cancer Res. 45, 4714-4726.
5. Hagiwara, A., Takahashi, T., Ueda, T., Iwamoto, A. and Torii, T. (1987) Activated carbon particles as anti-cancer drug carrier into regional lymph nodes. Anti-cancer Drug Design 1, 313-321.
6. Hagiwara, A., Takahashi, T., Lee, M., Sakakura, C., Shoubayashi, S., Tashima, S., Yamamoto, A. and Muranishi, S. (1993) Selective delivery of etoposide to intraperitoneal tissues using a new dosage format: etoposide microcrystals suspended in oil. Anti-Cancer Drugs 4, 27-31.
7. Hibbs, J. B. Jr., Lambert, L. H., Jr. and Remington, J. S. (1972) Control of carcinogenesis: a possible role for the activated macrophages. Science 177, 998-1000.
8. Kakutani, T., Yamaoka, K., Hashida, M. and Sezaki, H. (1985) A new method of assessment of drug disposition in muscle: application of statistical moment theory to local perfusion system. J. Pharmacokinet. Biopharm. 13, 609-613
9. Lee, J. S., Takahashi, T., Hagiwara, A., Yoneyama, C., Itoh, M., Sasabe, T., Muranishi, S. and Tashima, S. (1995) Safety and efficacy of intraperitoneal injection of etoposide in oil suspension in mice with peritoneal carcinomatosis. Cancer Chemother. Pharmacol. 36, 211-216.
10. Levin, V. A. (1986) Clinical anticancer pharmacology: some phar- macokinetic considerations. Cancer Treat. Rev. 13, 61-76.
11. Litterst, C. L., Torres, I. J., Arnold, McGunagle, S., Furner, D. R., Sikic, B. I. and Guarino, A. M. (1982) Absorption of antineoplastic drugs following large-volume i.p. administration to rats. Cancer Treat. Rep. 66, 147-155.
12. Lukas, G., Brindle, S. D. and Greengard, P. (1990) The route of absorption intraperitoneally administered compounds. J. Pharmacol. Exp. Ther. 178, 562-566.
13. Meyer, M. C. and Guttman, D. E. (1970) Dynamic dialysis as a method for studying protein binding I: factors affecting the kinetics of dialysis through a cellophane membrane. J. Pharm. Sci. 59, 33-38.
14. Miyazaki, S., Hashiguchi, N., Sugiyama, M., Takada, M. and Morimoto, Y. (1986a) Fibrinogen microspheres as novel drug delivery systems for antitumor drugs. Chem. Pharm. Bull. 34, 1370-1375.
15. Miyazaki, S., Hashiguchi, N., Hou, W.-M., Yokouchi, C. and Takada, M. (1986b) Antitumor effect of fibrinogen microparticles containing Adriamycin on Ehrlich ascites carcinoma in mice. Chem. Pharm. Bull. 34, 2632-2636.
16. Nara, E., Masegi, M., Hatono, T. and Hashida, M. (1992) Pharmacokinetic analysis of drug absorption from muscle based on a physiological diffusion model: effect of macromolecular size on absorption. Pharm. Res. 9, 161-168.
17. Nicolson, G. L. (1984) Cell surface molecules and tumor metastasis: regulation of metastatic phenotypic diversity. Exp. Cell Res. 150, 3-22.
18. Ozawa, S., Sugiyama Y., Mitsuhashi, Y. (1989) Kinetic analysis of cell killing effect induced by cytosine arabinoside and cisplatin in relation to cell cycle phase specificity in human colon cancer and chinese hamster cells. Cancer Res. 49, 3823-3828.
19. Sezaki, H. and Hashida, M. (1984) Macromolecule-drug conjugates in targeted cancer chemotherapy. CRC Crit. Rev. Ther. Drug Carrier Syst. 1, 1-38.
20. Sezaki, H., Takakura, Y. and Hashida, M. (1989) Soluble macromolecular carriers for the delivery of antitumor drugs. Adv. Drug Delivery Rev. 3, 247-266.
21. Tabata, Y. and Ikada, Y. (1990a) Drug delivery systems for antitumor activation of macrophages. Crit. Rev. Ther. Drug Carrier Syst. 7, 121-148.
22. Tabata, Y. and Ikada, Y. (1990b) Macrophage activation for antitumor function by muramyl dipeptide-protein conjugates J. Pharm. Pharmcol. 42, 13-19.
23. Yamaoka, Y., Nakagawa, T. and Uno T. (1978) Statistical moments in pharmacokinetics. J. Pharmacokinet. Biopharm. 6, 547-558.